At the time of writing, Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $16.56, up 8.88%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CNTA shares have gain 6.36% over the last week, with a monthly amount glided 26.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on July 21, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $30. Previously, Needham started tracking the stock with Buy rating on May 28, 2025, and set its price target to $35. On May 08, 2025, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $30 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $38 on March 31, 2025. TD Cowen initiated its recommendation with a Buy. Morgan Stanley upgraded its rating to Overweight for this stock on September 20, 2024, and upped its price target to $26. In a note dated September 19, 2024, B. Riley Securities initiated an Buy rating and provided a target price of $33 on this stock.
For the past year, the stock price of Centessa Pharmaceuticals plc ADR fluctuated between $9.10 and $19.09. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $16.56 at the most recent close of the market. An investor can expect a potential return of 26.81% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -13.05%, Pretax Profit Margin comes in at -14.7%, and Net Profit Margin reading is -14.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.57 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.22 points at the first support level, and at 13.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.80, and for the 2nd resistance point, it is at 19.03.
Ratios To Look Out For
It is important to note that Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] has a current ratio of 14.37. As well, the Quick Ratio is 14.37, while the Cash Ratio is 4.34. Considering the valuation of this stock, the price to sales ratio is 146.86, the price to book ratio is 5.73.
Transactions by insiders
Recent insider trading involved Accardi Mario Alberto, President, Orexin Program, that happened on Jul 29 ’25 when 8322.0 shares were sold. Officer, Accardi Mario Alberto completed a deal on Jul 29 ’25 to buy 8322.0 shares. Meanwhile, Chief Business Officer Weinhoff Gregory M sold 10000.0 shares on Jul 25 ’25.
